Dr. Greg Sullivan
Chairman & Chief Science Officer
Greg Sullivan, MD, who co-founded Bridge Therapeutics with the goal of helping patients beyond the walls of his own medical practice, has 25 years of experience conducting human studies for new drugs. Since 2003, he has performed numerous buprenorphine studies, including FDA safety and efficacy studies for every buprenorphine product currently approved for the U.S. market. He is board-certified in both addiction medicine and internal medicine and treats chronic pain patients at his practice in Birmingham, Ala.
David H. Bergstrom, Ph.D.
Chief Operating Officer
Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has overseen and been intimately involved in moving new products from the research phase to eventual successful commercial production and launch across numerous therapeutic areas and dosage form delivery technologies. Dave has experience in large, small, semi-virtual and contract development companies. He earned his Ph.D., M.S. and B.S. degrees in Pharmaceutics, Pharmaceutical Chemistry and Pharmacy from the University of Utah, The University of Michigan and Ferris State University, respectively.
Tim Peara, MBA
President & Finance Director
Tim Peara, MBA, brings to Bridge Therapeutics over 30 years’ experience in institutional investments and technology start-ups. He has contributed significantly to the growth and strategy of major players in finance (Wells Fargo, Prudential, Lehman) and industry (Koch, GE, Bechtel, United Technologies). He has also built and led teams while consulting to a variety of businesses, especially to energy tech. Throughout his career he has negotiated and structured investments, conducted due diligence and built financial models. Tim also has considerable international experience and foreign language skills. Tim Peara holds a BA in Latin American Studies from Wesleyan University, Connecticut and an MBA in Finance & International Business from the University of Chicago’s Booth School of Business.
Alton S. Kelley
Director of Business Development
Mr. Kelley has worked in the pharmacy, marketing and business development space throughout his career. Mr. Kelley has a B.B.A. from the University of Alabama with a Major in Business Management and a Minor in Computer Science.
Mr. Mullin has over 20 years of experience in finance restructuring consulting and asset management. He is the founder of Joseph E. Mullin LLC, where he has worked on projects for a variety of companies in the retail, energy and media space. He previously worked at Millennium Global, Invesco, WL Ross and Goldman Sachs. He has an AB from Harvard College.
After 7 years of TV reporting on issues like the Opioid Crisis and the Funding of Mental Health from Boise, Idaho to southern Mississippi. Wagner joins Bridge Therapeutics to manage business and networking. Ms. Wagner is a graduate of the University of Alabama where she majored in Telecommunications with a minor in Addictive Disorders and Recovery. With her education and coverage of the opioid epidemic, Ms. Wagner has experience working with leaders focused on solving this crisis and victims struggling with addiction.